# Amador Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amador-bioscience-2

- Industry: Healthcare
- Headquarters: Hangzhou, China
- Website: www.amadorbio.cn
- Latest round: Series B (Oct 2, 2021)
- Investors on record: 6

## About

Based in Hangzhou, China, and established in 2018, Amador Bioscience is a contract research organization about translational science and clinical pharmacology that provides services such as clinical pharmacology, laboratory testing, clinical project management, and regulatory reporting that meet international standards. The company has a clinical pharmacology, laboratory testing and clinical research team with rich experience in industry research and development services. At present, it has provided many Chinese and American innovative drug R&D companies with professional services on multiple projects from preclinical, clinical development to regulatory declaration, and post-marketing. 

The company provides clinical pharmacology, laboratory testing, clinical project management, and regulatory reporting that meet international standards. Clinical pharmacology focuses on modeling & simulation of FIH dose selection, data analysis and reporting of preclinical.  Laboratory services focus on non-clinical and clinical sample bioanalysis methodology development, validation and sample testing. Clinical trial project management focuses on providing clinical project management for domestic and foreign innovative drug research and development companies. In addition, it can also provides data analysis that meets international standards and generate complete application materials.

The company plans to strengthen its clinical pharmacology business, expand global bioanalytical services, and further improve global early clinical development capabilities, and introduce talents. Moreover, the company will acquire Ann Arbor Pharmacometrics Group.

## Funding rounds

- Series B, Oct 2, 2021 — Hong Shan, MSA Capital, Hillhouse Investment, Co-Win Ventures
- Series A, Nov 17, 2020 — Co-Win Ventures, AnlongMed Investment, Hangzhou Huaan Enterprise Management

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A, Series B
- AnlongMed Investment — Series A
- Hangzhou Huaan Enterprise Management (https://capitalatlas.ai/funds/hangzhou-huaan-enterprise-management) — Series A
- Hong Shan — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B